{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T04:42:19Z","timestamp":1784522539667,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","award":["PEC # 18-203"],"award-info":[{"award-number":["PEC # 18-203"]}],"id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","award":["PEC # 18-203"],"award-info":[{"award-number":["PEC # 18-203"]}],"id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","award":["PEC # 18-203"],"award-info":[{"award-number":["PEC # 18-203"]}],"id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","award":["PEC# 19-001"],"award-info":[{"award-number":["PEC# 19-001"]}],"id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","award":["PEC # 18-203"],"award-info":[{"award-number":["PEC # 18-203"]}],"id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","award":["PEC # 18-203"],"award-info":[{"award-number":["PEC # 18-203"]}],"id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","award":["PEC # 18-203"],"award-info":[{"award-number":["PEC # 18-203"]}],"id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Medications for opioid use disorder are evidence-based, guideline-recommended treatments. While buprenorphine can be prescribed in nonspecialized office-based settings, it is underutilized. Using a multifaceted implementation initiative, the Veterans Health Administration (VHA) sought to expand access to buprenorphine in nonspecialized office-based settings, including primary care clinics. The purpose of this qualitative evaluation was to assess and describe primary care clinicians\u2019 perspectives on delivering buprenorphine care during the first year of the initiative.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Using a snowball sampling approach, individualized emails were sent to primary care clinicians participating in a VHA initiative (<jats:italic>n<\/jats:italic>\u2009=\u200943) inviting them to be interviewed. Individual semi-structured interviews were conducted September 2019 through January 2020, and were audio-recorded, transcribed, and analyzed using thematic analysis. The Consolidated Framework for Implementation Research (CFIR), a meta-theoretical framework of five domains associated with successful adoption of interventions, was used to organize findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 43 clinicians invited, 19 responded and were interviewed (44.2%). Findings represented two CFIR domains: Inner Setting and Characteristics of Individuals. For Inner Setting, three themes were identified as influencing implementation during the first year of the initiative. Clinicians reported a shared receptivity to implement buprenorphine, organizational support from pharmacy services and leadership, as well as cohesive relationships among implementation team members and collaboration with outside clinics. Noted barriers included fit within primary care workflows and lack of staff, time and access to onsite laboratory services and buprenorphine. For Characteristics of Individuals, two themes were identified that may facilitate clinicians\u2019 willingness to provide buprenorphine care. Namely, clinicians reported positive attitudes about and experiences delivering opioid use disorder care and a willingness to learn\/do something new.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>While implementation strategies should be tailored to individual clinic needs, prioritizing factors identified in this evaluation may support successful implementation of buprenorphine delivery in primary care.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13722-025-00568-9","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:40:05Z","timestamp":1745988005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Implementing buprenorphine for opioid use disorder in veterans health administration primary care: a qualitative analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Aline","family":"Lott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa N.","family":"Danner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Malte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope A.","family":"Salameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bachowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildi J.","family":"Hagedorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline C.","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Saxon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan S.","family":"Trim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"568_CR1","doi-asserted-by":"publisher","unstructured":"Singh JA. National U.S. time-trends in opioid use disorder hospitalizations and associated healthcare utilization and mortality. PLoS ONE. 2020;15(2). https:\/\/doi.org\/10.1371\/journal.pone.0229174","DOI":"10.1371\/journal.pone.0229174"},{"key":"568_CR2","first-page":"S200","volume":"24","author":"N Hagemeier","year":"2018","unstructured":"Hagemeier N. Introduction to the opioid epidemic: the economic burden on the healthcare system and impact on quality of life. Am J Manag Care. 2018;24:S200\u20136.","journal-title":"Am J Manag Care"},{"key":"568_CR3","doi-asserted-by":"publisher","unstructured":"Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657\u2013\u200967. Epub 20110310. https:\/\/doi.org\/10.1111\/j.1526-4637.2011.01075.x. PubMed PMID: 21392250.","DOI":"10.1111\/j.1526-4637.2011.01075.x"},{"key":"568_CR4","unstructured":"Economic Burden of Illness in Opioid Use Disorder (OUD) and Medication-Assisted Treatments. AJMC. Accessed July 19, 2023. Available from:"},{"key":"568_CR5","unstructured":". VA\/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Accessed September 24, 2021. Available from: https:\/\/www.healthquality.va.gov\/guidelines\/MH\/sud\/VADoDSUDCPG.pdf"},{"key":"568_CR6","unstructured":"American Society of Addiction Medicine. The ASAM National practice guideline for the treatment of opioid use disorder. Available from: https:\/\/www.asam.org\/quality-care\/clinical-guidelines\/national-practice-guideline"},{"issue":"4","key":"568_CR7","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/add.13238","volume":"111","author":"YI Hser","year":"2016","unstructured":"Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, et al. Long-term outcomes after randomization to Buprenorphine\/naloxone versus methadone in a multi-site trial. Addiction. 2016;111(4):695\u2013705. https:\/\/doi.org\/10.1111\/add.13238. Epub 2015\/11\/26.","journal-title":"Addiction"},{"issue":"2","key":"568_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1176\/appi.ps.201300256","volume":"65","author":"CP Thomas","year":"2014","unstructured":"Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014;65(2):158\u201370. https:\/\/doi.org\/10.1176\/appi.ps.201300256. Epub 2013\/11\/20.","journal-title":"Psychiatr Serv"},{"issue":"1\u20132","key":"568_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.drugalcdep.2009.12.008","volume":"108","author":"N Meader","year":"2010","unstructured":"Meader N. A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis. Drug Alcohol Depend. 2010;108(1\u20132):110\u20134. https:\/\/doi.org\/10.1016\/j.drugalcdep.2009.12.008. Epub 2010\/01\/16.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"568_CR10","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/add.12863","volume":"110","author":"E Evans","year":"2015","unstructured":"Evans E, Li L, Min J, Huang D, Urada D, Liu L, et al. Mortality among individuals accessing Pharmacological treatment for opioid dependence in California, 2006-10. Addiction. 2015;110(6):996\u20131005. https:\/\/doi.org\/10.1111\/add.12863. Epub 20150315.","journal-title":"Addiction"},{"issue":"10208","key":"568_CR11","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560\u201379. https:\/\/doi.org\/10.1016\/S0140-6736(19)32229-9. Epub 20191023.","journal-title":"Lancet"},{"issue":"2","key":"568_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1370\/afm.1595","volume":"12","author":"E Hutchinson","year":"2014","unstructured":"Hutchinson E, Catlin M, Andrilla CH, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128\u201333. https:\/\/doi.org\/10.1370\/afm.1595. PubMed PMID: 24615308; PubMed Central PMCID: PMC3948759.","journal-title":"Ann Fam Med"},{"key":"568_CR13","doi-asserted-by":"publisher","first-page":"108811","DOI":"10.1016\/j.drugalcdep.2021.108811","volume":"225","author":"K Foti","year":"2021","unstructured":"Foti K, Heyward J, Tajanlangit M, Meek K, Jones C, Kolodny A, et al. Primary care physicians\u2019 preparedness to treat opioid use disorder in the united States: A cross-sectional survey. Drug Alcohol Depend. 2021;225:108811. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108811. Epub 20210618.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"568_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13011-020-00312-3","volume":"15","author":"RL Haffajee","year":"2020","unstructured":"Haffajee RL, Andraka-Christou B, Attermann J, Cupito A, Buche J, Beck AJ. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. Subst Abuse Treat Prev Policy. 2020;15(1):69. https:\/\/doi.org\/10.1186\/s13011-020-00312-3. Epub 20200914.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"568_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","volume":"78","author":"AS Huhn","year":"2017","unstructured":"Huhn AS, Dunn KE. Why aren\u2019t physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1\u20137. https:\/\/doi.org\/10.1016\/j.jsat.2017.04.005. Epub 2017\/05\/31.","journal-title":"J Subst Abuse Treat"},{"key":"568_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugpo.2017.11.021","volume":"54","author":"B Andraka-Christou","year":"2018","unstructured":"Andraka-Christou B, Capone MJ. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release Naltrexone in U.S. office-based practices. Int J Drug Policy. 2018;54:9\u201317. PubMed PMID: 29324253.","journal-title":"Int J Drug Policy"},{"key":"568_CR17","first-page":"3019","volume":"15","author":"JR DeFlavio","year":"2015","unstructured":"DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA Jr. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015;15:3019. Epub 20150204. PubMed PMID: 25651434.","journal-title":"Rural Remote Health"},{"key":"568_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.28627","author":"EJ Austin","year":"2023","unstructured":"Austin EJ, Chen J, Briggs ES, Ferro L, Barry P, Heald A, et al. JAMA Netw Open. 2023;6(8):e2328627. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.28627. Epub 20230801. Integrating Opioid Use Disorder Treatment Into Primary Care Settings."},{"issue":"1","key":"568_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13722-021-00263-5","volume":"16","author":"EJ Hawkins","year":"2021","unstructured":"Hawkins EJ, Danner AN, Malte CA, Blanchard BE, Williams EC, Hagedorn HJ, et al. Clinical leaders and providers\u2019 perspectives on delivering medications for the treatment of opioid use disorder in veteran affairs\u2019 facilities. Addict Sci Clin Pract. 2021;16(1):55. https:\/\/doi.org\/10.1186\/s13722-021-00263-5. Epub 2021\/09\/08.","journal-title":"Addict Sci Clin Pract"},{"key":"568_CR20","doi-asserted-by":"publisher","unstructured":"Hagedorn HJ, Gustavson AM, Ackland PE, Bangerter A, Bounthavong M, Clothier B et al. Advancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD): an Implementation Trial in Eight Veterans Health Administration Facilities. J Gen Intern Med. 2022. Epub 2022\/01\/05. https:\/\/doi.org\/10.1007\/s11606-021-07274-7. PubMed PMID: 34981352; PubMed Central PMCID: PMC8722660.","DOI":"10.1007\/s11606-021-07274-7"},{"key":"568_CR21","doi-asserted-by":"publisher","first-page":"108729","DOI":"10.1016\/j.drugalcdep.2021.108729","volume":"224","author":"NJ Kazerouni","year":"2021","unstructured":"Kazerouni NJ, Irwin AN, Levander XA, Geddes J, Johnston K, Gostanian CJ, et al. Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden. Drug Alcohol Depend. 2021;224:108729. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108729. Epub 20210424.","journal-title":"Drug Alcohol Depend"},{"key":"568_CR22","doi-asserted-by":"publisher","unstructured":"Radic M, Parlier-Ahmad AB, Wills B, Martin CE. Social determinants of health and emergency department utilization among adults receiving buprenorphine for opioid use disorder. Drug Alcohol Depend Rep. 2022;3. https:\/\/doi.org\/10.1016\/j.dadr.2022.100062. Epub 20220514.","DOI":"10.1016\/j.dadr.2022.100062"},{"issue":"1","key":"568_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamapsychiatry.2022.3673","volume":"80","author":"H Dong","year":"2023","unstructured":"Dong H, Stringfellow EJ, Russell WA, Jalali MS. Racial and ethnic disparities in buprenorphine treatment duration in the US. JAMA Psychiatry. 2023;80(1):93\u20135. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.3673. PubMed PMID: 36350592; PubMed Central PMCID: PMC9647560.","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"568_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/08897077.2020.1787299","volume":"41","author":"AJ Gordon","year":"2020","unstructured":"Gordon AJ, Drexler K, Hawkins EJ, Burden J, Codell NK, Mhatre-Owens A, et al. Stepped care for opioid use disorder train the trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within veterans health administration facilities. Subst Abus. 2020;41(3):275\u201382. https:\/\/doi.org\/10.1080\/08897077.2020.1787299. Epub 2020\/07\/23.","journal-title":"Subst Abus"},{"issue":"12","key":"568_CR25","doi-asserted-by":"publisher","first-page":"e2137238","DOI":"10.1001\/jamanetworkopen.2021.37238","volume":"4","author":"EJ Hawkins","year":"2021","unstructured":"Hawkins EJ, Malte CA, Gordon AJ, Williams EC, Hagedorn HJ, Drexler K, et al. Accessibility to medication for opioid use disorder after interventions to improve prescribing among nonaddiction clinics in the US veterans health care system. JAMA Netw Open. 2021;4(12):e2137238. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.37238. Epub 2021\/12\/07.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"568_CR26","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","volume":"89","author":"BC O\u2019Brien","year":"2014","unstructured":"O\u2019Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245\u201351..0000000000000388. PubMed PMID: 24979285.","journal-title":"Acad Med"},{"key":"568_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-4-50","author":"LJ Damschroder","year":"2009","unstructured":"Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009. https:\/\/doi.org\/10.1186\/1748-5908-4-50. 4:50. Epub 2009\/08\/12.","journal-title":"Implement Sci"},{"key":"568_CR28","volume-title":"The logic of sampling","author":"E Babbie","year":"2004","unstructured":"Babbie E. The logic of sampling. 10th ed. Belmont, CA: Wadsworth\/Thomson; 2004.","edition":"10"},{"key":"568_CR29","volume-title":"Qualitative organizational research","author":"G Symon","year":"2012","unstructured":"King N. Doing template analysis. In G.Symon and C. Cassell (Eds). Qualitative organizational research. London: Sage; 2012."},{"issue":"2","key":"568_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qualitative Res Psychol"},{"issue":"1","key":"568_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59\u201382.","journal-title":"Field Methods"},{"key":"568_CR32","volume-title":"Qualitative data analysis: A methods sourcebook","author":"M Miles","year":"2014","unstructured":"Miles M, Huberman A, Saldana J. Qualitative data analysis: A methods sourcebook. Thousand Oaks, CA: Sage; 2014."},{"issue":"1","key":"568_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.9740\/mhc.2021.01.035","volume":"11","author":"LM Mailloux","year":"2021","unstructured":"Mailloux LM, Haas MT, Larew JM, DeJongh BM. Development and implementation of a physician-pharmacist collaborative practice model for provision and management of Buprenorphine\/naloxone. Ment Health Clin. 2021;11(1):35\u20139. https:\/\/doi.org\/10.9740\/mhc.2021.01.035. Epub 20210108.","journal-title":"Ment Health Clin"},{"issue":"9","key":"568_CR34","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1177\/00048674211048410","volume":"56","author":"R Ng","year":"2022","unstructured":"Ng R, El-Den S, Stewart V, Collins JC, Roennfeldt H, McMillan SS, et al. Pharmacist-led interventions for people living with severe and persistent mental illness: A systematic review. Aust N Z J Psychiatry. 2022;56(9):1080\u2013103. Epub 20210924. doi: 10.1177\/00048674211048410. PubMed PMID: 34560826.","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"568_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/JAN.0000000000000455","volume":"33","author":"AO Radmall","year":"2022","unstructured":"Radmall AO, Calder S, Codell N, Kelley AT, Hawkins E, Jones AL, et al. Roles and perceptions of nurses during implementation of a medication treatment for opioid use disorder National initiative. J Addict Nurs. 2022;33(2):70\u20139. 1097\/JAN.0000000000000455. PubMed PMID: 35640210.","journal-title":"J Addict Nurs"},{"issue":"5","key":"568_CR36","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/add.14522","volume":"114","author":"A Bisaga","year":"2019","unstructured":"Bisaga A. What should clinicians do as Fentanyl replaces heroin? Addiction. 2019;114(5):782\u20133. Epub 20190120. doi: 10.1111\/add.14522. PubMed PMID: 30661265.","journal-title":"Addiction"},{"issue":"9","key":"568_CR37","doi-asserted-by":"publisher","first-page":"e2334540","DOI":"10.1001\/jamanetworkopen.2023.34540","volume":"6","author":"LC Chambers","year":"2023","unstructured":"Chambers LC, Hallowell BD, Zullo AR, Paiva TJ, Berk J, Gaither R, et al. Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of Fentanyl. JAMA Netw Open. 2023;6(9):e2334540. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.34540. Epub 20230905.","journal-title":"JAMA Netw Open"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00568-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00568-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00568-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:40:12Z","timestamp":1745988012000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00568-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["568"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00568-9","relation":{"references":[{"id-type":"doi","id":"10.1001\/jamanetworkopen.2023.28627","asserted-by":"subject"}]},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This evaluation was classified as quality improvement by the Institutional Review Board at Veterans Affairs (VA) Puget Sound and did not require human subjects\u2019 approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have completed the ICMJE uniform disclosure form and declare: all authors had financial support from the U.S. Department of Veterans Affairs (VA) or the University of Washington for the submitted work; AS reports royalties from UpToDate, Inc. and is a member of DSMB DoD Pharmacotherapies for Alcohol and Substance Abuse Consortium; AG reports an honorarium from UpToDate, Inc. and serves on the board of directors for the American Society of Addiction Medicine, the Association for Multidisciplinary Education and Research in Substance Use and Addiction, and the International Society of Addiction; there are no other relationships or activities that could appear to have influenced the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}